Hyaluronic acid oligosaccharide-chitosan bionic temperature-sensitive gel entrapped with hemangioma stem cell-derived extracellular vesicles
By carrying extracellular vesicles from hemangioma stem cells in the hyaluronic acid oligosaccharide-modified chitosan hydrogel, a bionic thermosensitive gel was formed, which solved the problems of angiogenesis and microcirculation reconstruction in diabetic wounds, and achieved Significant tissue repair and healing effects.
Patent Information
- Application Number
- CN202310523509.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively promote angiogenesis and microcirculation reconstruction of diabetic wounds. Traditional dressings mainly inhibit bacteria and absorb wound exudate, and lack the function of promoting tissue repair.
Develop a hyaluronic oligosaccharide-chitosan bionic thermosensitive gel containing extracellular vesicles from hemangioma stem cells. Using hyaluronic oligosaccharide-modified chitosan hydrogel as a carrier, using cells derived from hemangioma stem cells As a therapeutic active substance for pro-angiogenesis, external vesicles combine with hydroxyethyl cellulose and sodium bicarbonate to regulate the phase change point, osmotic pressure and degradation rate of the gel to form an optimized therapeutic system.
This treatment system significantly promotes the microcirculation reconstruction and healing of diabetic wounds, and verifies its effectiveness in ischemic tissue repair through in vivo and in vitro experiments, especially in rat diabetes wound model. It demonstrates good proangiogenesis and wounds. Healing effect.
Smart Images

Figure HDA0004221974710000011 
Figure HDA0004221974710000021 
Figure HDA0004221974710000031
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedical materials, and in particular relates to a hyaluronic acid oligosaccharide-chitosan biomimetic thermosensitive gel encapsulating extracellular vesicles derived from hemangioma stem cells, which is used for promoting tissue repair, in particular angiogenesis and microcirculation reconstruction of ischemic tissues. Background Art
[0002] Tissue repair and regeneration in ischemic areas have been a hot research area in recent years and are also the key to the treatment of many diseases, such as acute vascular injury caused by trauma, thrombosis, stroke, chronic and difficult-to-heal wounds caused by diabetes, etc. Among them, diabetic wounds, also known as diabetic ulcers or diabetic foot, are a typical diabetic complication that occurs in about 20% of diabetic people, many of whom eventually require amputation, which is the main cause of disability in diabetes. In the complex pathological mechanism of this disease, microcirculatory disorders caused by vascular lesions are an important factor, which is also related to wound oxygen supply, effector cell chemotaxis, cytokine production and transport, and is closely related to inflammation and oxidative stress. In current clinical practice, the treatment of diabetic ulcers is mainly based on traditional debridement and antibacterial therapy, and the main function of the wound dressings used is to inhibit bacteria and absorb wound exudate. Therefore, it is urgent to design and develop a wound dressing that can effectively promote angiogenesis and microcirculation reconstruction and can comprehensively improve the wound environment.
[0003] Extracellular vesicles (EVs) are nanovesicles with a phospholipid bilayer structure secreted by cells. They contain a variety of proteins and miRNAs, which can serve as the main medium for intercellular communication and regulate a variety of cell functions. In recent years, EVs have been applied to many medical fields such as disease diagnosis and treatment. Infantile hemangioma is a benign tumor common in infants and young children, characterized by abnormal proliferation of vascular endothelial cells. Hemangioma stem cells (HemSC) are a type of CD133-positive cells isolated from infantile hemangioma. They can promote cell angiogenic differentiation and peripheral vascular proliferation through autocrine and paracrine effects, and are believed to play a key regulatory role in the progression of hemangioma disease.
[0004] Chitosan (CS) is a widely available natural polymer material with antibacterial and anti-inflammatory properties. The hydrogel constructed from CS and sodium β-glycerophosphate (β-GP) is a classic thermosensitive hydrogel with advantages such as low toxicity, neutral pH, and mild phase transition conditions, but it also has defects such as high osmotic pressure and strong cationic charge.
[0005] Based on the current status of the prior art, the present invention intends to provide an oHA / CS biomimetic thermosensitive gel encapsulating HemSC-EVs. The hyaluronic acid (HA) of the present invention is an important component of the extracellular matrix (ECM), has good biocompatibility and moisturizing and lubricating ability, and is widely used in the fields of medicine and cosmetics. Hyaluronic acid oligosaccharide (oHA) is a degradation product of HA. Compared with macromolecular HA (molecular weight can usually reach hundreds of thousands of Da), oHA also has some additional biological functions. Studies have shown that oHA can activate receptors such as Src, FAK, ERK-1 / 2, thereby promoting angiogenesis and wound healing. Summary of the invention
[0006] The present invention aims to provide an oHA / CS biomimetic thermosensitive gel EVs@oHA / CS encapsulating HemSC-EVs gel The present invention effectively promotes the reconstruction of microcirculation in diabetic wounds by cleverly utilizing EVs derived from pathological tissues such as HemSC as therapeutic active substances that promote angiogenesis. In order to further improve the efficacy of EVs in treating diabetic wounds, the present invention has developed a novel chitosan-based thermosensitive gel biomimetic-modified by hyaluronic acid oligosaccharide (oHA) as its drug delivery carrier.
[0007] In the present invention, a strategy is proposed to modify chitosan thermosensitive gel by using the interaction between the negative charge on oHA and the positive charge on HA. The addition of oHA shields the excess positive charge on CS, making the hydrogel exhibit a variety of properties that are more conducive to EVs administration. At the same time, oHA can be used as an ECM mimic to further improve the biocompatibility of the hydrogel and promote cell adhesion and spreading. In addition, we also screened and optimized the basic formulation of the hydrogel, such as adding hydroxyethyl cellulose (HEC) to adjust the gel phase transition point, adding sodium bicarbonate (NaHCO3) to adjust the gel osmotic pressure and pH, and adding gelatin to adjust the gel degradation rate.
[0008] In summary, the present invention extracts HemSC-EVs as therapeutic active substances that promote angiogenesis, encapsulates them in the carefully designed and optimized oHA biomimetic-modified chitosan hydrogel, and develops a new therapeutic system EVs@oHA / CSgel for tissue repair, especially microcirculation reconstruction of ischemic tissues.
[0009] The present invention thoroughly evaluates the physicochemical properties and in vitro angiogenesis-promoting ability of the hydrogel therapeutic system, and further verifies its therapeutic effects of angiogenesis-promoting and wound healing in a rat diabetic wound model.
[0010] The present invention uses differential centrifugation to obtain EVs from the supernatant of HemSC in vitro cell culture, and the specific acquisition method is as follows: ① When the HemSC is cultured to about 80% of the bottom of the culture flask, the original culture medium is discarded, rinsed twice with phosphate buffered saline (PBS), and serum-free culture medium is added in a certain proportion; ② The cells are placed in a cell culture incubator and continue to be cultured for a certain period of time; ③ The cell culture supernatant is collected; ④ The cell culture supernatant is centrifuged at 4°C, 200g for 5min to remove floating cells; ⑤ The supernatant in the previous step is centrifuged at 4°C, 10000g for 30min to remove cell debris; ⑥ The supernatant in the previous step is centrifuged at 4°C, 100000g for 70min to collect EVs; ⑦ The precipitate in the previous step is resuspended with an appropriate amount of PBS, and centrifuged again at 4°C, 100000g for 70min, and the precipitate is the purified EVs.
[0011] In the above operation: the ratio of serum-free culture medium added in step ① is 0.05-0.2 mL per square centimeter of culture area, preferably 0.12-0.15 mL per square centimeter of culture area; the time for serum-free culture to collect EVs in step ② is 24-72 hours, preferably 48 hours.
[0012] Preparation of EVs@oHA / CS by the present invention gel The method is as follows: ① Dissolve the prescribed amount of CS, HEC, oHA, and gelatin in dilute acid to obtain solution A; ② Dissolve the prescribed amount of β-GP and NaHCO3 in water to obtain solution B; ③ Resuspend the prescribed amount of EVs in PBS to obtain solution C; ④ At a certain temperature and a certain stirring speed, add solution B drop by drop to solution A; ⑤ Add solution C to the above mixture to obtain the hydrogel to be formed (hydrogel presolution); ⑥ Place the hydrogel presolution in a 37°C incubator and wait for about 3 minutes to form a hydrogel.
[0013] In the above operation: the dilute acid in step ① is 0.05-0.2 mol / L hydrochloric acid or acetic acid, preferably 0.1 mol / L hydrochloric acid; the temperature in step ④ is 0-20°C, preferably 10°C; the stirring speed in step ④ is 50-1000 rpm, preferably 200 rpm. The content of each substance in the final hydrogel in the prescription is: CS addition amount 1-3%, preferably 1.5-2%; HEC addition amount 0-0.2%, preferably 0.05-0.1%; oHA addition amount 0-0.5%, preferably 0.1-0.25%; gelatin addition amount 0-1%, preferably 0.5-0.75%; β-GP addition amount 1-6%, preferably 2-3%; NaHCO3 addition amount 0-0.5%, preferably 0.05-0.2%; HenSC-EV addition amount is 0-100 μg / mL in terms of protein content and 0-1×10 in terms of particle number. 11 / mL, preferably, 40-60 μg / mL in terms of protein content and 4×10 10 ~6×10 10 Pieces / mL.
[0014] Beneficial effects of the present invention
[0015] The present invention obtains EVs from HemSCs, whose morphology, particle size, and characteristic protein expression are consistent with the general characteristics of EVs. In one embodiment, HemSC-EVs exhibit good angiogenic activity and can be used as therapeutic active substances that promote angiogenesis.
[0016] The present invention obtains an oHA biomimetic modified chitosan-based thermosensitive hydrogel. In one embodiment, the oHA modified hydrogel exhibits softer and more elastic deformability. In another embodiment, the oHA modified hydrogel exhibits better biocompatibility.
[0017] The present invention obtains a hyaluronic acid-chitosan biomimetic thermosensitive gel treatment system EVs@oHA / CS encapsulating extracellular vesicles derived from hemangioma stem cells gel In one embodiment, the therapeutic system exhibits good wound healing and angiogenesis promoting effects.
[0018] In summary, the present invention obtains EVs derived from HemSC as a therapeutic active substance that promotes angiogenesis, and encapsulates it in oHA biomimetic modified chitosan-based hydrogel to construct a therapeutic system EVs@oHA / CS gel The present invention evaluated EVs@oHA / CS through multiple in vivo and in vitro experiments. gel The characteristics and efficacy of EVs@oHA / CS were investigated, and the effects of the treatment system on wound healing and angiogenesis were evaluated in a rat diabetic wound model. gel It can be used as a tissue repair material with application prospects, especially suitable for the recovery of ischemic damaged tissues and reconstruction of microcirculation. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Characterization and identification of HemSC-EVs
[0020] (A) Transmission electron microscopy photograph;
[0021] (B) NTA particle size distribution;
[0022] (C) Western-blot protein detection results.
[0023] Figure 2 .EVs@oHA / CS gel Preparation
[0024] (A) Thermosensitive gel forming process;
[0025] (B)CS gel , oHA / CS gel ,EVs@CS gel ,EVs@oHA / CS gel Modulus-temperature scanning curve during the programmed temperature rise from 25 to 40°C.
[0026] Figure 3 .EVs@oHA / CS gel Characterization
[0027] (A) Modulus-time scanning curves of hydrogel at 10, 25, 32, and 37°C;
[0028] (B) Rheological frequency scanning curve after hydrogel formation;
[0029] (C) Rheological strain scanning curve after hydrogel formation;
[0030] (D) Osmotic pressure of hydrogel extract;
[0031] (E) pH of the hydrogel extract;
[0032] (F) Scanning electron microscopy image of the hydrogel.
[0033] Figure 4 .EVs@oHA / CS gel In vitro angiogenic activity study
[0034] (A) Representative images of scratch assay;
[0035] (B) Schematic diagram of the scratch test setup;
[0036] (C) Quantitative results of reduced scratch area;
[0037] (D) Representative images of hydrogel-cell co-culture experiments;
[0038] (E) Quantification of the number of viable cells in the co-culture experiment;
[0039] (F) Quantification of cell viability in co-culture experiments.
[0040] Figure 5 .EVs@oHA / CS gel Study on the efficacy of drugs in promoting wound healing and microcirculation reconstruction in diabetic rats
[0041] (A) Representative wound photos;
[0042] (B) Change trend of wound shape and area;
[0043] (C) Curve of wound area changing with healing time;
[0044] (D) Wound area reduction values on days 7 and 14;
[0045] (E) Laser Doppler blood flow imaging photograph of the wound area;
[0046] (F) Quantitative results of blood perfusion index on day 17. DETAILED DESCRIPTION
[0047] To facilitate those skilled in the art to understand the contents of the present invention, the technical solutions and corresponding evaluation characterization solutions of the present invention will be further described below in conjunction with specific embodiments, but the following content should not limit the scope of protection requested by the claims of the present invention in any way.
[0048] Example 1. Extraction, characterization and identification of HemSC-EVs
[0049] Methods: When HemSCs were cultured to about 80% of the bottom of the culture flask, the original culture medium was discarded, rinsed twice with phosphate buffered saline (PBS), and 0.135 mL of serum-free culture medium was added per square centimeter of culture area. The cells were placed in a cell culture incubator and cultured for 48 hours, and the cell culture supernatant was collected. The cell culture supernatant was centrifuged at 4°C, 200g for 5 minutes to remove floating cells. The supernatant was centrifuged at 4°C, 10000g for 30 minutes to remove cell debris. The supernatant was centrifuged at 4°C, 100000g for 70 minutes to collect EVs. The precipitate was resuspended with an appropriate amount of PBS and centrifuged again at 4°C, 100000g for 70 minutes. The precipitate was the purified EVs.
[0050] The protein content of HemSC-EVs was determined using a BCA kit, the morphology was photographed using a transmission electron microscope (TEM), and the particle size distribution and particle density were analyzed using a nanoparticle tracking analyzer (NTA). In addition, Western-blot technology was used to identify the characteristic proteins, among which CD9, CD63, and TSG101 were positively expressed proteins, and Calnexin was a negatively expressed protein.
[0051] Results: When the amount of serum-free culture medium added to extract EVs was 0.135 mL per square centimeter of culture area, the amount of protein extracted from EVs per 100 mL of culture supernatant was 151.3 μg, and the number of EVs particles was 1.47×10 11 TEM results showed that HemSC-EVs had the typical appearance of teacup-like membrane vesicles, with a particle size of about 50 to 150 nm ( Figure 1 A). Particle size measurement shows that its particle size distribution peak is 106nm ( Figure 1 B). Western-blot results showed that HemSC-EVs highly expressed CD9, CD63, and TSG101 proteins, and lowly expressed Calnexin protein ( Figure 1 C), indicating that the extracted HemSC-EVs have high purity and contain less impurities.
[0052] Example 2. EVs@oHA / CS gel Preparation
[0053] Methods: Taking the preparation of 15mL hydrogel as an example, the prescribed amount of CS, HEC, oHA, and gelatin were stirred and dissolved in 12mL 0.1mol / L hydrochloric acid, recorded as solution A; the prescribed amount of β-GP and NaHCO3 were dissolved in 2mL purified water, recorded as solution B; the prescribed amount of HemSC-EVs was resuspended in 1mL PBS, recorded as solution C. Under magnetic stirring at 10℃ and 200rpm, solution B was slowly added to solution A, and then solution C was added to the mixture. This hydrogel pre-liquid was placed in a 37℃ water bath, and gel was formed within 5min.
[0054] To further compare the effects of oHA and EVs on the phase transition temperature of hydrogels, we used a rotational rheometer to measure the phase transition temperature of CS. gel 、oHA / CS gel 、EVs@CS gel and EVs@oHA / CS gel Four hydrogel precursors were subjected to temperature scans. The rheometer used a 20 mm diameter parallel plate fixture, set the Gap Size to 3000 μm, the scanning frequency to 2.0 rad / s, the strain to 2%, the programmed temperature range from 25°C to 40°C, and the heating rate to 0.5°C / min.
[0055] Results: Figure 2 As shown in A, the hydrogel precursor is in liquid state and can quickly form a gel after being placed at 37°C. Figure 2 As shown in B, CS gel 、oHA / CS gel 、EVs@CS gel and EVs@oHA / CS gel The sol-gel phase transition temperatures under the heating condition were 31.4°C, 34.6°C, 33.3°C and 35.1°C, respectively, all meeting the actual drug administration requirements.
[0056] Example 3. EVs@oHA / CS gel Characterization
[0057] Method: EVs@oHA / CS was prepared according to the method in Example 2 gelThe hydrogel precursor was scanned at four temperatures of 10°C, 25°C, 32°C, and 37°C using a rotational rheometer to plot the modulus-time curve. The rheometer used a 20mm diameter parallel plate fixture, set the Gap Size to 3000μm, the scanning frequency to 2.0rad / s, and the strain to 2%.
[0058] EVs@oHA / CS gel The hydrogel pre-liquid was kept at 37°C for 12 hours to allow the hydrogel to be fully formed. The frequency and strain scans were performed using a rotational rheometer. The rheometer used a parallel plate fixture with a diameter of 20 mm and set the Gap Size to 3000 μm. During the frequency scan, the strain was fixed at 2%, and the frequency was set from 0.1 rad / s to 20 rad / s. During the strain scan, the frequency was fixed at 2.0 rad / s, and the strain was set from 0.1% to 1000%.
[0059] Obtaining hydrogel extract and measuring osmotic pressure and pH: CS gel 、oHA / CS gel 、EVs@CS gel and EVs@oHA / CS gel The four hydrogel pre-liquids were placed in a 6-well cell culture plate to form a liquid surface of about 5 mm in height, and placed in a 37°C incubator to form a hydrogel. 0.5 mL of physiological saline was added to each well per square centimeter of culture area, and the well plate was returned to the incubator for incubation for 24 hours to obtain a hydrogel extract. The osmotic pressure and pH value were measured using an ice point osmometer and a pH meter.
[0060] The formed hydrogel was taken, pre-frozen at -20°C for 24 hours, and freeze-dried in a freeze dryer. The freeze-dried gel block was fractured in liquid nitrogen, and the fracture surface was sprayed with gold and the microstructure was observed using a scanning electron microscope.
[0061] Results: Figure 3 As shown in A, EVs@oHA / CS gel It can maintain a liquid state for more than 20 minutes at 10°C and 25°C, and can quickly form a gel at 32°C and 37°C, which is convenient for practical applications. gel The frequency sweep and strain sweep results are shown in Figure 3 B and Figure 3 C, indicating that the gel treatment system has the characteristics of softness and high elastic deformability. The osmotic pressure and pH value of the hydrogel extract are shown in Figure 3 D and Figure 3 As shown in E, the osmotic pressure and pH of the hydrogel are physiologically safe. gel The SEM images are as follows Figure 3 As shown in F, it presents a typical three-dimensional network structure.
[0062] Example 4. EVs@oHA / CS gel In vitro angiogenic activity study
[0063] Method: CS was prepared according to the method in Example 2 gel 、oHA / CS gel 、EVs@CS gel and EVs@oHA / CS gel Four hydrogel precursors.
[0064] Scratch test of human umbilical vascular endothelial cells (HUVEC): a 24 mm diameter, 0.4 μm pore size The device was prepared by adding 3 mL of hydrogel pre-liquid to it and placed in a 37°C incubator to wait for it to form. HUVECs were inoculated in a 6-well cell culture plate and cultured until about 95% of the bottom of the well plate was covered. A 200 μL pipette tip and a ruler were used to make a straight scratch on the bottom surface, and then the original culture medium was discarded and rinsed twice with PBS to remove floating cells. Then, reduced serum culture medium (containing 5% FBS) and the hydrogel were added. The device was placed back in the incubator for continued culture. Scratch photos were taken at 0, 12, 24, 36, and 48 hours, and the scratch area was quantified using image J software.
[0065] HUVEC co-culture experiment on hydrogel surface: 0.6 mL of hydrogel pre-liquid was added to each well of a 12-well cell culture plate and placed in a 37°C incubator to wait for formation. 5 HUVEC cells were inoculated into the 12-well cell culture plate covered with hydrogel and cultured in a 37°C incubator. At 12, 24, 48, and 72 hours, CalceinAM / PI live / dead cell staining reagent was added to the plate, and the cells in the field of view were counted using a fluorescence microscope.
[0066] result: Figure 4 B is a schematic diagram of the HUVEC scratch experiment. Figure 4 As shown in A, the quantitative results are Figure 4 C. The results show that EVs@oHA / CS gel Both oHA and EVs released in the therapeutic system have certain pro-angiogenic effects, among which EVs have a stronger effect. Figure 4 D is a representative photo of HUVEC growth on the hydrogel surface, where the live cell counts of each group at each time point are as follows: Figure 4 E, and the cell survival rate is shown in 4F. The results show that the chitosan gel modified with oHA can greatly improve its biocompatibility, and the cells on its surface have a higher survival rate. EVs@oHA / CS gelThe therapeutic system can effectively promote the proliferation, spreading and growth of HUVEC on its surface.
[0067] Example 5. EVs@oHA / CS gel Efficacy study on promoting diabetic wound healing and microcirculation reconstruction in rats Method: After fasting for 12 hours, SD rats were intraperitoneally injected with 55 mg / kg streptozotocin to establish type I diabetes model. Fasting blood glucose values were measured on the 3rd and 7th days after modeling, and rats with both measurements above 11.1 mmol / L were considered to have successfully established the model. The hair in the modeling area on the back of the rat was shaved, and a silicone fixing ring with an outer diameter of 30 mm, an inner diameter of 20 mm, and a thickness of 2 mm was sutured with surgical thread, and the full-thickness skin in the area with a diameter of 16 mm was cut off to obtain the SD rat diabetic wound model.
[0068] EVs@oHA / CS gel Group and oHA / CS gel Each rat in each group was smeared with 1.5 mL of the corresponding hydrogel, the EVs solution group was dripped with 1.5 mL of saline containing the same concentration of EVs, and the control group (untreated group) was dripped with 1.5 mL of saline. The above treatment measures were repeated twice a week, and wound photos were taken at each administration, and the wound area was quantified using image J software. On the 10th and 17th days, the wound blood perfusion was evaluated using a laser Doppler blood flow imager.
[0069] Results: This example successfully established a diabetic wound model in SD rats. Typical wound photos of each group during the treatment process are shown in the following figure. Figure 5 As shown in A, the shape and size of the wound change as Figure 5 B. The curve of the average wound area of each group changing with time is shown in Figure 5 C, the wound area reduction values on the 7th and 14th days were as follows Figure 5 D. The results showed that on day 14, the average wound area of the EVs solution group was only 58.5% of that of the untreated group, while the EVs@oHA / CS gel The average wound area of the group was only 26.9% of the untreated group. This result shows that HemSC-EVs can effectively promote wound healing, while EVs@oHA / CS gel It has a better effect in promoting wound healing, which may be because the treatment system can slowly release EVs as a reservoir of EVs. In addition, through the wound area change curve, it can be found that the two treatment groups with the addition of EVs showed better healing speed in the second week (7th to 14th day). This shows that the pro-angiogenic effect of HemSC-EVs is more effective in promoting overall tissue repair in the middle and late stages of wound healing (migration and remodeling), which is consistent with previous literature reports. The picture of laser Doppler blood flow imaging is as follows Figure 5E shows the quantitative results of the blood perfusion index on day 17. Figure 5 As shown in F, the results showed that the blood perfusion level of the EVs aqueous solution group was 63.1% higher than that of the untreated group, while EVs@oHA / CS gel The blood perfusion level of the group treated with oHA / CS was 126.8% higher than that of the untreated group. This result further verified the angiogenic effect of HemSC-EVs and the gel Hydrogel carriers can enhance the therapeutic effects of EVs.
Claims
1. A biological dressing, characterized in that: The dressing comprises extracellular vesicles derived from hemangioma stem cells (HemSC-EVs) and a biomimetic modified chitosan thermosensitive gel (oHA / CS gel ).
2. The biological dressing according to claim 1, characterized in that: The hemangioma stem cell-derived extracellular vesicles (HemSC-EVs) are extracted from the serum-free cell culture supernatant of HemSC cultured in vitro, and the cell surface expresses CD9, CD63, and TSG101 proteins but does not express Calnexin protein.
3. The biological dressing according to claim 1, characterized in that: The biomimetic modified chitosan thermosensitive gel (oHA / CS gel ) was prepared from purified water, chitosan (CS), hyaluronic acid oligosaccharide (oHA), gelatin, hydroxyethyl cellulose (HEC), sodium β-glycerophosphate (β-GP) and sodium bicarbonate (NaHCO3).
4. The biological dressing according to claim 3, characterized in that: The preparation process comprises the following steps: three aqueous phases are stirred and mixed in a constant temperature water bath to form a hydrogel pre-liquid after mixing.
5. The biological dressing according to claim 4, characterized in that: During the preparation process, the amount of CS added is 1-3%, preferably 1.5-2%; the amount of HEC added is 0-0.2%, preferably 0.05-0.1%; the amount of oHA added is 0-0.5%, preferably 0.1-0.25%; the amount of gelatin added is 0-1%, preferably 0.5-0.75%; the amount of β-GP added is 1-6%, preferably 2-3%; the amount of NaHCO3 added is 0-0.5%, preferably 0.05-0.2%.
6. The biological dressing according to any one of claims 3 to 5, characterized in that: During the preparation process, HemSC-EVs were uniformly dispersed in the hydrogel system. The amount of HenSC-EV added was 0-100 μg / mL based on protein content and 0-1×10 based on particle number. 11 / mL, preferably, 40-60 μg / mL in terms of protein content and 4×10 10 ~6×10 10 Pieces / mL.
7. Use of the biological dressing according to any one of claims 1 to 6 in preparing a material for accelerating vascular reconstruction and promoting wound repair.
8. The use according to claim 7, characterized in that The material is applied to the reconstruction of microcirculation of diabetic wounds.
